FIELD: medicine.
SUBSTANCE: invention relates to the field of medicine and the chemical and pharmaceutical industry, namely to a drug for the treatment and/or prevention of coronavirus infection COVID-19 in the form of a capsule containing molnupiravir and excipients.
EFFECT: expansion of the range of anti-COVID drugs.
1 cl, 1 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR THE TREATMENT OF CORONAVIRUS INFECTION CAUSED BY SARS-CoV-2 | 2021 |
|
RU2775966C1 |
| THERAPEUTIC AGENT AGAINST CORONAVIRUS INCLUDING AN ELAEOCARPUS SYLVESTRIS EXTRACT | 2021 |
|
RU2780346C1 |
| PEPTIDES WITH ANTIVIRAL ACTIVITY | 2024 |
|
RU2834861C1 |
| 2-(IMIDAZOL-4-YL)-ETHANAMIDE OF PENTANEDIOIC ACID OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR TREATING COVID-19 AND SYMPTOMS THEREOF | 2021 |
|
RU2824607C2 |
| METHODS OF TREATING CORONAVIRUS INFECTIONS | 2021 |
|
RU2825648C1 |
| ANTI-SARS-COV-2 VIRAL AGENT ANTIPROVIR | 2020 |
|
RU2738885C1 |
| ANTI-SARS-CoV-2-VIRAL PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | 2020 |
|
RU2764444C1 |
| USING DALARGIN FOR PRODUCING AGENTS FOR TREATING COVID-19 CORONAVIRUS INFECTION | 2020 |
|
RU2728939C1 |
| TREATMENT OF CORONAVIRUS INFECTION | 2021 |
|
RU2837859C1 |
| NEW COMBINED PHARMACEUTICAL COMPOSITION AND MEDICINAL PRODUCT FOR TREATMENT OF CORONAVIRUS INFECTION | 2022 |
|
RU2806643C1 |
